Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acro Biomedical Co's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Acro Biomedical Co's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:6748's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Acro Biomedical Co (ROCO:6748) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Acro Biomedical Co 5-Year Yield-on-Cost % Related Terms
ROCO:6748 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Acro Biomedical Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acro Biomedical Co 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acro Biomedical Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Acro Biomedical Co's 5-Year Yield-on-Cost % falls into.
Acro Biomedical Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Acro Biomedical Co (ROCO:6748) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Acro Biomedical Co and its competitors. According to the industry distribution chart, Acro Biomedical Co ranks #999999 out of 150 companies in the Biotechnology industry.
Is Acro Biomedical Co's 5-Year Yield-on-Cost % too high?
Acro Biomedical Co's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Acro Biomedical Co ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acro Biomedical Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acro Biomedical Co's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acro Biomedical Co ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Acro Biomedical Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.60, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Acro Biomedical Co and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acro Biomedical Co's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Acro Biomedical Co (ROCO:6748) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$32.20, compared to a current price of NT$178.00 — trading 452.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Acro Biomedical Co's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Acro Biomedical Co (ROCO:6748), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acro Biomedical Co (ROCO:6748) Overvalued in 2026?
Based on GuruFocus' analysis, Acro Biomedical Co stock appears to be overvalued.
The current stock price of NT$178.00 is trading 452.8% above its estimated GF Value™ of NT$32.20.
GuruFocus considers Acro Biomedical Co to be Significantly Overvalued.
Key valuation signals for ROCO:6748:
5-Year Yield-on-Cost %: 0.00
GF Value™: NT$32.20 vs. price of NT$178.00 (452.8% above fair value)
No single metric tells the full story. See the ROCO:6748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acro Biomedical Co Ltd is a company whose technical team integrates the Research and development capabilities of Taiwan's major scientific research units and medical centers to jointly develop equipment for repairing organs and tissues in various parts of the human body. It mainly focuses on orthopedics, dentistry, cardiovascular specialists, ophthalmology, surgery, wound care, Medical equipment used in sports injuries and other specialties.
61GF Score
Get the complete analysis for ROCO:6748
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6748 has been successfully added to your 
